New hope for tough blood disorder: Three-Drug combo enters trial
NCT ID NCT07204041
Summary
This study is testing whether a combination of three drugs—selinexor, thalidomide, and dexamethasone—can help control Langerhans cell histiocytosis (LCH) in adults whose disease has come back or hasn't responded to previous treatments. It will involve about 40 participants at multiple centers in China. The main goal is to see if this treatment can delay the disease from getting worse, while also monitoring side effects and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
Conditions
Explore the condition pages connected to this study.